Emerald-3, Successor-2 and Optimum-02 studies secure late-breaker spots.
ApexOnco Front Page
Recent articles
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
And the company says it won’t need to carry out another trial.
A fresh licensing deal tidies up years of work between the two companies.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
And that could affect the drug's third-line accelerated approval.
